Thaum Lub Ob Hlis 10, 2025, CARsgen Therapeutics tshaj tawm tias thawj tus neeg mob uas tau kho nrog kev kho mob BCMA CAR-T allogeneic uas tsim los ntawm lub platform THANK-u Plus ™, tau ua tiav cov lus teb tiav (sCR) thiab qhov tsis zoo ntawm cov kab mob seem tsawg kawg nkaus (MRD) ntawm qhov kev ntsuam xyuas Hnub-28. Tsim tawm hauv tsev, lub platform THANK-u Plus ™ yog ib qho thev naus laus zis allogeneic CAR-T tshiab uas tsim los kov yeej cov teeb meem nkag mus rau hauv kev kho mob CAR-T.
Tus neeg mob, uas tau kuaj pom tias muaj tus kab mob relapsed/refractory multiple myeloma, hom IgA-λ (R-ISS Theem II), tau dhau los ua peb txoj kev kho mob ua ke nrog rau kev hloov pauv hlwb ntawm tus kheej. Tom qab tus kab mob loj hlob tom qab kev kho mob tsis ntev los no, tus neeg mob tau raug sau npe rau hauv kev sim tshuaj. Tom qab txhaj tshuaj CAR T cell ntawm qib qis tshaj plaws raws li cov txheej txheem kho mob, tus neeg mob tau muaj tus kab mob tso tawm cytokine Qib 1 (CRS), uas tau tswj hwm zoo nrog cov tshuaj antipyretics thiab tocilizumab, thiab tus neeg mob tsis tau qhia txog tus kab mob immune effector cell-associated neurotoxicity syndrome (ICANS) lossis lwm yam teeb meem kev tiv thaiv kab mob CAR-T, qhia txog kev nyab xeeb zoo.
Txoj kev kho mob CAR-T no yog tsim los rau kev kho mob ntawm cov mob relapsed/refractory multiple myeloma (R/R MM) thiab relapsed/refractory plasma cell leukemia (R/R PCL). Cov ntaub ntawv hloov tshiab ntxiv yuav raug kwv yees rau hauv ib nrab xyoo tom ntej no.
Tam sim no, tseem muaj ntau qhov kev sim tshuaj kho mob qog noj ntshav tshiab hauv Suav teb nrhiav cov neeg mob. Kev sab laj txog cov tshuaj tshiab thiab cov thev naus laus zis, koj tuaj yeem tiv tauj Beijing South Region Oncology Hospital International Department.
Xov Tooj: 4008803716
Email：myimmnet@163.com
Cov ntaub ntawv siv los ua piv txwv
2. https://www.prnasia.com/
Lub sijhawm tshaj tawm: Lub Ob Hlis-11-2025